关键词

IgA nephropathy; IgM deposition; pathological classification; Oxford classification; clinical features; diagnosis; treatment; prognosis; biomarkers; individualized treatment; epidemiological characteristics

全文

PDF

参考

[1] Roberts, I. S., et al. (2016). The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney
Int, 89(1), 1-5.
[2] Trimarchi, H., et al. (2017). Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working
Group. Kidney Int, 91(5), 1014-21.
[3] Tomino, Y., et al. (1999). IgM nephropathy: a relatively common form of idiopathic glomerulonephritis. Kidney Int Suppl, 70, S13-6.
[4] Coppo, R., et al. (2021). Advances in the diagnosis and treatment of IgA nephropathy. J Nephrol, 34(4), 893-903.
[5] Floege, J., et al. (2014). Comprehensive classification of glomerular diseases: key to successful diagnosis and treatment. Kidney Int,
86(1), 198-207.[6] Shimizu, A., et al. (2011). Clinicopathological analysis of diffuse crescentic glomerulonephritis: comparison of patients with and without
antineutrophil cytoplasmic antibody. Clin Exp Nephrol, 15(2), 196-203.
[7] D'Amico, G. (2004). Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol, 24(3), 179-
96.
[8] Katafuchi, R., et al. (1993). Fundamental importance of pathological examinations for patients with IgA nephropathy. Nephron, 64(3),
455-62.
[9] Manno, C., et al. (2017). A novel scoring system for estimating progression in IgA nephropathy. Kidney Int, 91(2), 365-74.
[10] Li, Y. F., et al. (2019). Chinese multi-center study of the treatment of IgA nephropathy: design and baseline data. Zhonghua Yi Xue Za
Zhi, 99(4), 264-70.
[11] Xie, J., et al. (2014). The clinical characteristics and outcomes of IgA nephropathy with nephrotic syndrome. Sci Rep, 4, 3232.
[12] Feehally, J., et al. (2018). Comprehensive Clinical Nephrology. 6th Edition. Elsevier.
[13] Lv, J., et al. (2017). Advances in the Diagnosis and Treatment of IgA Nephropathy. J Am Soc Nephrol, 28(4), 1069-82.
[14] Maixnerová, D., et al. (2015). Treatment of IgA nephropathy: an update. Ann Transl Med, 3(7), 92.
[15] Lai, K. N., et al. (2004). Clinical features and the natural course of IgA nephropathy - Part I. Semin Nephrol, 24(2), 254-65.
[16] Fellström, B. C., et al. (2017). Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a doubleblind, randomised, placebo-controlled phase 2b trial. Lancet, 389(10084), 2117-27.